Pfizer, Actavis End Patent Fight Over Generic Lipitor

Law360, Los Angeles (October 12, 2011, 3:13 PM EDT) -- A Delaware federal judge on Tuesday dismissed pharmaceutical giant Pfizer Inc.’s patent infringement suit against Iceland-based Actavis Group HF over a generic version of anti-cholesterol drug Lipitor, after the parties announced they had reached a settlement.

Tuesday's dismissal ends one of a series of patent suits brought by Pfizer over abbreviated new drug applications for generic Lipitor. Terms of the settlement were not immediately available.

New York-based Pfizer lodged a complaint alleging patent infringement in August 2010, after Actavis filed an ANDA seeking federal approval to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.